Pt Prodia Widyahusada Tbk · IDX:PRDA
Pt Prodia Widyahusada Tbk — 9M 2020 Earnings Presentation
42 slides from Pt Prodia Widyahusada Tbk's earnings presentation, November 2020
Slide 1: 9M 2020 Results Update
9M 2020 Results Update Nov 2020 prodia.co.id This presentation has been prepared specifically by Prodia. The content of this presentation may not be used, duplicated or transmitted in any form without the written consent from Prodia. All rights reserved.
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by PT Prodia Widyahusada (the "Company") solely for use in connection with the analyst presentation relating to the Company. The information contained in this presentation is strictly confidential and is provided to you solely for your reference. By vie
Slide 3: List of Figures
List of Figures Market & Business Highlights 04 Business & Financial Updates 28 Economy Outlook (COVID-19 Impact) 05 Revenue 29 Covid-19 Test Global Market 06 Quarterly Revenue 30 Post COVID-19 Points of Impact 07 No. of Visit and Rev/Visit 31 Digital Transformation on Healthcare 08 Test Volume & Te
Slide 4: Market & Business Highlights
Market & Business Highlights 4
Slide 5: Economic Outlook 2020
Economic Outlook 2020 The Impact of Coronavirus Outbreak Economic Outlook 2020-2021 Post COVID-19 Outbreak Year Indonesia’s Govt’ World Bank OECD* ADB** IMF*** (Sep 20) (Oct 20) (Sep 20) (Sep 20) (Oct 20) Global N/A -5.2% -4.5% N/A -4.4% 2020 Indonesia -1.7% to -0.6% -2.0 to -1.6% -3.3 -1.0% -1.5% G
Slide 6: COVID-19 Test Global Market
COVID-19 Test Global Market COVID-19 Detection Kits Market (incl. RT-PCR assay kits, Diagnostic Centers, Oropharyngeal Swab) Global Statistic Regional Outlook Market 2026 North Share America (2020) >$13Bn CAGR >26% 2024 (2020-26) -3% Europe GLOBAL MARKET SHARE 2022 United States CAGR 2020-2026 2021
Slide 7: Post Launch COVID-19 Points of Impact for Healthcare System & Life Science Industry
Post Launch COVID-19 Points of Impact for Healthcare System & Life Science Industry The Southeast Asia Macro Trends Future Healthcare Engagement with System and Medicine Demand Healthcare Pharmaceutical & Supply Professionals Industry Environment Fluctuating demand Decline of healthcare Fallin
Slide 8: Digital Transformation in Indonesia's Healthcare Services
Digital Transformation in Indonesia’s Healthcare Services Accelerated on Technology Adoption for Healthcare Indonesia is the largest and There are 318,000 health fastest growing internet apps available globally on economy in Southeast Asia. Google Play and Apple app Expecting compound annual stores,
Slide 9: Shifting to Digital Services
Shifting to Digital Services Indonesian Consumer Survey – Post Covid Condition Have you used ore done any of the following since COVID-19 started? User Growth and Intent to Use after COVID-19 User Intent to Activities Growth Continue Online fitness 29% 67% Wellness app 35% 69% Telemedicine: physical
Slide 10: Largest Network & Market Share in Independent Clinical Lab Industry
Largest Network & Market Share in Independent Clinical Lab Industry Market Share by Revenue Independent Clinical Labs (2018 & 2019) 38.8% 39.2% 28.2% 2018 26.9% 2019 33.0% 33.9% Source: IQVIA Analysis (2020) Note: Next 5 Players consists of: 1) Kimia Farma, 2) Pramita, 3) Parahita, 4) BioMedika , 5)
Slide 11: Comprehensive Service Offering
Comprehensive Service Offering Targets Multiple Customer Segments Routine Testing Non-Laboratory Testing Specialty Clinics Esoteric Testing Referral Lab Services Doctor Consultation Predictive, Preventive, General Medical Preventive Treatment Personalized Package Check-Up Services Testing Walk-In Cu
Slide 12: Prodia Laboratories
Prodia Laboratories Indonesian Pioneer in Clinical Laboratory Testing Received SMK3 accreditation and OHSAS 2015, along Established with the Award as "Diagnostic Services Company of the professional Year 2015" from Frost & Sullivan 2019 management team Opened the first green building used for
Slide 13: Scalable Hub and Spoke Model
Scalable Hub and Spoke Model Significant Economies of Scale Achieved Prodia Clinical Labs, Centralized information Hospitals and Other Prodia Referral with integrated IT “Hub and spoke” model Clinics may refer tests to Lab Services platform that connects offers scalable platform PRLS (PRLS) each lab
Slide 14: 2019-2020 Awards
2019-2020 Awards WOW Brand Award From Markplus Inc. Service Quality Award From Carre Service Quality Monitoring Corporate Image Award From Frontier Consulting Group & Marketing Magazine Top Brand Award From Frontier Consulting Group & Marketing Magazine Social Media Award From Marketing Ma
Slide 15: Senior Leadership and Management Team
Senior Leadership and Management Team Experienced, Professional Management Team with a Track Record in Delivering Superior Growth and Innovation Years of Years of Years of Years of Years of 47 Experience 47 Experience 37 Experience 31 Experience 33 Experience Andi Gunawan Endang Scott Andrew Lukas S
Slide 16: Shareholder Composition
Shareholder Composition PT Prodia Utama Bio Majesty Pte. Ltd. Public 57% 18% 25% Contract Research, therapy Distributor for Research and banking of healthcare Organization stem cell products PT Prodia Widyahusada Tbk Occupational In Vitro Health Diagnostics Nationwide Outlet Network across Indonesia
Slide 17: Growth Strategy
ail Growth Strategy
Slide 18: Growth Strategy
Growth Strategy (Pre-COVID-19) A Near-term B Long-term Expand our presence and grow Focus on the development of next- our network of outlets in both generation diagnostic existing and new markets in technologies for precision medicine Indonesia Upgrade existing clinical laboratories to provide wider
Slide 19: Near Term Growth Plan
Near Term Growth Plan (Pre-COVID-19) Prodia’s Network Expansion Plan 2016 - 2021 1 2 3 4 Expand Network Upgrade Clinical Enhance Operating Focus on of Outlets Labs Efficiency Quality 31 regional referral labs Upgrade up to 39 clinical labs to PHC3 Clinics Up to 33 additional clinical labs over next
Slide 20: Leader in Next Generation Technology
Leader in Next Generation Technology Research Evaluation Laboratory Laboratory Mass Spectrometry & Molecular Separation Next Generation Diagnostic Science Laboratory Laboratory Laboratory Anatomical Advance Pathology Immunology Laboratory Laboratory Personalized Treatment The Concept of Precision Me
Slide 21: FY2016-2020 Total Outlets & Development Targets
Business Updates FY2016-2020 Total Outlets & Development Targets 129 118 9 2 FY2016 259 Outlets Clinical Labs POC Outlets Hospital Labs Specialty Clinic 136 130 11 5 FY2017 283 Outlets Clinical Labs POC Outlets Hospital Labs Specialty Clinic 143 128 14 7 FY2018 292 Outlets Clinical Labs POC Outlets
Slide 22: Response to COVID-19
Develop COVID-19 Related Test: PCR & Serological testing Create New Ways of Service: Cleanliness, Safety, Convenience Broaden Access Channel for Customer: Physical & On-line RESPONSE Accelerate Digital Transformation: Enhance Digital Platform TO COVID-19 Strengthen Internal Business Process: Agile a
Slide 23: Deliver Solution for Customer Needs
DELIVER SOLUTION FOR CUSTOMER NEEDS Respond to People Behavior Changing and Customer’s Voice Services & Lab Online Marketing Product Lab Testing In Facilities and Education Innovation COVID-19 Pandemic Activities • e-Prodia • Digital • Complete Testing from • COVID-19 Testing • Home/Office Service C
Slide 24: RT-PCR SARS COV-2 RNA Test in Prodia
RT-PCR SARS COV-2 RNA Test in Prodia May 2020 July 2020 Sep 2020 Manual platform Referral Lab Jakarta Referral Lab Jakarta and 3 Max 600 – 800/day Regional Referral Lab TAT: D/D+1 Referral Lab Jakarta (Sby, Mks, Mdn) Max 450/day Max 280/day Total: +/- 2,000 tests/day TAT: D+1 TAT: D/D+1 Total: 450 t
Slide 25: New Innovation & Enhancement
Customer Centric Model eRegistration Prodia in your Car Service New Innovation & Enhancement Prodia Home Customer Service Centric Tele-Consultation Tele-Radiology • General Practitioners • Clinical Pathologists Tele-Health* • Internist • Clinical Nutritionist • Sport Medicine 25
Slide 26: Technology to Increase Customer Satisfaction
Technology to Increase Customer Satisfaction Online Order via Prodia Mobile Online Results via Prodia Mobile 26
Slide 27: Keep Communicating & Educating Customer
Keep Communicating & Educating Customer Live Interviews More than 300 Webinars
Slide 28: 9M2020 Business & Financial Updates
9M2020 Business & Financial Updates 28
Slide 29: 9M2020 Revenue (Unaudited)
Business Updates 9M2020 Revenue (Unaudited) Revenue (in IDR Billion) FY16-FY19 CAGR +8.7% 9M19-9M20 growth: -3.0% 1,744.3 1,599.8 1,466.0 Revenue slowing 1,359.0 1,238.9 1,202.1 down by -3.0% due 1,041.8 1,116.7 to volume test per visit weakened. 2016 2017 2018 2019 9M 9M 9M 9M 2017 2018 2019 2020 2
Slide 30: Quarterly Revenue Trends (Unaudited)
Business Updates Quarterly Revenue Trends (Unaudited) Quarterly Revenue 2016 – 2020 (in IDR Billion) 2Q20-3Q20 growth: 104.8% 1Q20-2Q20 growth: -32.0% 550 Q3 2020, 544.8 500 3Q2020 YoY 450 Q1 2020, 2020 growth was higher 391.4 than YoY 3Q 2019 400 growth since 2017. 2018 350 2017 2016 300 Q2 2020, 2
Slide 31: 9M2020 Number of Visit and Revenue per Visit
Business Updates 9M2020 Number of Visit and Revenue per Visit Number of Visits (in ‘000) Revenue per Visit (in IDR ‘000) FY16-FY19 CAGR +1.2% 9M19-9M20 growth +5.4% FY16-FY19 CAGR +7.4% 9M19-9M20 growth -8.0% 2,482 2,503 2,482 2,571 1,950 1,790 1,748 1,850 678 670 644 639 616 586 582 547 2016 2017 2
Slide 32: 9M2020 Test Volume & Test per Visit
Business Updates 9M2020 Test Volume & Test per Visit Test Volume (in ‘000) Test per Visit FY16-FY19 CAGR +4.2% 9M19-9M20 growth -19.1% FY16-FY19 CAGR +3.0% 9M19-9M20 growth -23.3% 15,958 16,520 14,591 15,129 10,388 10,878 11,462 6.43 6.42 9,272 6.22 6.20 5.88 6.05 5.80 4.75 2016 2017 2018 2019 9M 9M
Slide 33: 9M2020 Customer Segments and Testing Types (Unaudited)
Business Updates 9M2020 Customer Segments and Testing Types (Unaudited) Walk-in Customers Doctor Referrals • Individual walk-in patients • Patients referred by doctors 31.3% • Out-of-pocket cash • Out-of-pocket cash 31.4% payment payment Diversified Customer Base External Referral Corporate clients
Slide 34: 9M2020 COVID-19 Test Revenue (Unaudited)
Business Updates 9M2020 COVID-19 Test Revenue (Unaudited) COVID-19 Test Revenue Contribution COVID-19 Test Revenue Breakdown by 9M2020 Customer Segment 9M2020 10.1% Corporate Clients 6.8% 24.4% Walk in SARS-CoV-2 RNA 21.0% (PCR COVID-19) Anti SARS-CoV-2 (Rapid/Serology) External Doctor Non COVID Tes
Slide 35: New Test Developments
Business Updates New Test Developments Value-based Lab Testing Predictive, Preventive & Targeted Diagnostic Pharmacogenomics Screening Therapy 1. NIPT (ProSafe) 28. Jak2 Mutation 41.Jak 2 Mutation 51. Warfarin Indiv Test 2. Telomere Analysis 29. Kidney Stone Analysis (FTIR) 42. Mutation EGFR (CYP2C9
Slide 36: The collateral damage of COVID-19: cardiovascular disease, the next pandemic wave
Did you know? The collateral damage of COVID-19: 50% of Heart cardiovascular disease, the next Attack victims have normal pandemic wave cholesterol. Finally, we provide PULS a blood test for the leading cause of Heart Attacks: Unstable Cardiac Lesion Rupture. PULS (Protein Unstable Lesion Signature)
Slide 37: Prodia Skin and Hair Genomics
Prodia Skin and Hair Genomics is a genomic test to identify skin and hair health condition and tendencies. The test consists of 3 (three) chapters, 6 groups, and 33 panels (trait) related to condition and nutrition adequacy of skin and hair.
Slide 38: 9M2020 EBITDA (Unaudited)
Financial Updates 9M2020 EBITDA (Unaudited) EBITDA (in IDR Billion) FY16-FY19 CAGR +14.8% 9M19-9M20 growth: +23.9% 316.0 30.0% 277.5 25.0% 239.1 EBITDA significantly 209.1 234.0 20.0% improves due to cost 155.8 166.0 188.8 . 18.1% 15.0% efficiency, revenue 16.3% 17.3% 15.4% recovery, and impact 19.5
Slide 39: 9M2020 Gross Profit & Net Income (Unaudited)
Financial Updates 9M2020 Gross Profit & Net Income (Unaudited) Gross Profit (in IDR Billion) Net Income (in IDR Billion) 9M19-9M20 growth: -9.4% 9M19-9M20 growth: +1.1% 722.3 121.0 122.3 98.9 106.5 646.0 654.5 10.2% 602.2 54.5% 57.8% 57.8% 58.3% 9.5% 9.5% 9.8% 9M2017 9M2018 9M2019 9M2020 9M2017 9M20
Slide 40: 9M2020 COGS & OPEX (Unaudited)
Financial Updates 9M2020 COGS & OPEX (Unaudited) COGS (in IDR Billion) OPEX (in IDR Billion) CAGR %COGS per sales 9M19-9M20 %COGS per CAGR %OPEX per sales 9M19-9M20 %OPEX per 2016-2019 -1.0% sales growth +9.2% 2016-2019 -1.6% sales growth -10.5% 703 75.0% 1,000 657 827 612 770 565 126 548 713 114 51
Slide 41: Financial Summary 9M2020 (Unaudited)
Financial Updates Financial Summary 9M2020 (Unaudited) (in IDR Bn) 9M2020 9M2019 Change Revenue 1,202.08 1238.89 -3.0% Gross Profit 654.54 722.27 -9.4% Gross Profit Margin 54.5% 58.3% -380 BPS EBIT 122.28 111.04 +10.1% EBIT Margin 10.2% 9.0% +120 BPS EBT 148.63 148.27 +0.2% EBT Margin 12.4% 12.0% +4
Slide 42: Thank You
Thank You For more information : PT Prodia Widyahusada Tbk Investor.Relation@prodia.co.id Prodia Tower, Jl. Kramat Raya No. 150, Jakarta 10430, Indonesia Phone +6221.3144182 ext. 3774, 3775 http://www.prodia.co.id 1500-830 e-prodia @prodia_lab Laboratorium Klinik Prodia prodia.co.id
PT Prodia Widyahusada — 9M 2020 Earnings Presentation on 6ix